Clinical trials: Glioma Tumor Recurrence
Benign Neoplasms, Brain, Brain Cancer
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
The purpose of this study is to determine the safety and utility of 5-aminolevulinic acid (ALA) for identifying your tumor during surgery. 5-ALA is not FDA approved at this time.
- Conditions
- Benign Neoplasms, Brain, Brain Cancer, Brain Neoplasms, Benign, Brain Neoplasms, Malignant
- Trial name
- NCT01445691
- Testing
- 5-ALA (Gliolan)
- Where
- 6 sites in United States
- Sponsor
- Constantinos Hadjipanayis
Glioblastoma Multiforme, Malignant Gliomas
Sunitinib to Treat Recurrent Brain Cancer
Background: One way tumors are able to grow is by forming new blood vessels that supply them with nutrients and oxygen. Sunitinib blocks certain proteins on the surface of tumor and blood vessel cells that are involved with the…
- Conditions
- Glioblastoma Multiforme, Malignant Gliomas, Anaplastic Gliomas
- Trial name
- NCT00923117
- Testing
- Sutent (sunitinib)
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- National Cancer Institute (NCI)
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors
The purpose of this study is to collect and store brain tissue samples and blood from children with brain cancer that will be tested in the laboratory.
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Cerebral Anaplastic Astrocytoma, Childhood Cerebral Astrocytoma
- Trial name
- NCT00919750
- Testing
- Cytology Specimen Collection Procedure
- Where
- 187 sites in United States, Australia and 4 more
- Volunteers
- 1,258 people
- Sponsor
- Children's Oncology Group
Recurrent Medulloblastoma
Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children
This study is a prospective single-center clinical study, which aims to observe and evaluate the efficacy and safety of apatinib combined with temozolomide and oral etoposide in the treatment of recurrent medulloblastoma in…
- Trial name
- NCT04501718
- Testing
- Apatinib Combined With Temozolomide and Etoposide Capsules
- Where
- China
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Beijing Sanbo Brain Hospital
Brain Tumors, Spinal Cord Tumors
Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma
The goal of this clinical research study is to learn if lapatinib when given in combination with temozolomide can help to control ependymoma that has come back after treatment. The safety of this combination will also be studied.
- Trial name
- NCT00826241
- Testing
- Temozolomide, Lapatinib
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Adult Glioblastoma, Adult Gliosarcoma
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
This phase I/II trial studies the side effects and best dose of temsirolimus when given together with sorafenib tosylate and to see how well they work in treating patients with glioblastoma that has come back.
- Conditions
- Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
- Trial name
- NCT00329719
- Testing
- Conventional Surgery, Laboratory Biomarker Analysis, Sorafenib Tosylate
- Where
- 190 sites in United States
- Volunteers
- 115 people
- Sponsor
- National Cancer Institute (NCI)
Glioma
Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor
This research study is testing the safety of a vaccination of cells called GM-K562 cells mixed with the participants own irradiated tumor cells.
- Trial name
- NCT00694330
- Testing
- GM-K562 Vaccination
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Massachusetts General Hospital
Cancer
Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors
This study aims to determine the efficacy of daily sirolimus and celecoxib, with low dose etoposide alternating with cyclophosphamide for pediatric participants with relapsed or refractory tumors.
- Trial name
- AflacST1502 (NCT02574728)
- Testing
- Sirolimus, Celecoxib, Etoposide
- Where
- 6 sites in United States
- Volunteers
- 46 people
- Sponsor
- Emory University
Glioblastoma, Adult
Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)
The purpose of this study is to test the side effects and efficacy of using Laser Interstitial Thermotherapy (LITT) combined with Pembrolizumab.
- Trial name
- NCT03277638
- Testing
- Pembrolizumab at 7 days prior, Pembrolizumab at 14 days post, Pembrolizumab at 35 days post
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Case Comprehensive Cancer Center
Recurrent Glioblastoma Multiforme, Progressive Glioblastoma Multiforme
Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma
To determine the safety and tolerability of the maximum dose for laboratory engineered Herpes Simplex Virus-1 in patients who would not be eligible for surgical resection of recurrent glioma To determine the safety and…
- Conditions
- Recurrent Glioblastoma Multiforme, Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma or Gliosarcoma
- Trial name
- M032-HSV-1 (NCT02062827)
- Testing
- M032 (NSC 733972)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Alabama at Birmingham
Glioblastoma, Recurrent Brain Neoplasm
Palliative 4pi Radiotherapy in Treating Patients With Recurrent Glioblastoma Multiforme
This pilot clinical trial studies the feasibility of palliative 4pi radiotherapy in treating patients with glioblastoma multiforme that has come back after standard chemoradiation.
- Trial name
- NCT02575027
- Testing
- Palliative Radiation Therapy, Questionnaire Administration, Radiation Therapy Treatment Planning and Simulation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Glioma, Glioblastoma
Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma
It was previously shown that [18F]Fluorodopa (FDOPA) PET imaging results in intended management changes in 41% of brain tumor patients.
- Conditions
- Glioma, Glioblastoma, Glioblastoma Multiforme
- Trial name
- NCT02176720
- Testing
- FDOPA PET
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- The Methodist Hospital Research Institute
Glioma
Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas
This study will examine the safety and effectiveness of peginterferon alpha-2b (PEG-Intron) alone and together with thalidomide in patients with gliomas (a type of brain tumor).
- Trial name
- NCT00047879
- Testing
- PEG-interferon alfa-2b, Thalidomide
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Malignant Glioma
Avastin / Irinotecan in Patients With Recurrent or Progressive Malignant Glioma
Malignant glioma are the most common and aggressive primary brain tumors in adults. Despite advances in multimodal treatment including surgery, radiation and chemotherapy, most patients have a dismal prognosis of 9-15 months…
- Trial name
- AVIRMA01-09 (NCT01144988)
- Testing
- Bevacizumab / Irinotecan
- Where
- 2 sites in Austria
- Volunteers
- 35 people
- Sponsor
- Medical University Innsbruck
Recurrent Glioblastoma
A Panobinostat Presurgery
In the current study, the investigators will evaluate intratumoral pharmacodynamic and pharmacokinetic data associated with the administration of the HDACI, Panobinostat, among recurrent GBM patients.
- Trial name
- CLBH589C (NCT01115036)
- Testing
- panobinostat
- Where
- United States
- Sponsor
- Duke University
Glioma, Adult
A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma
The primary purpose of this Phase II study is to evaluate the preliminary anti-tumor efficacy of HF1K16 in combination with Bevacizumab in patients with recurrent or progressive glioma.
- Trial name
- NCT07678684
- Testing
- HF1K16
- Where
- China
- Volunteers
- 30 people
- Sponsor
- HighField Biopharmaceuticals Corporation
Recurrent Malignant Glioma
Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients
This is an open label Phase 1b clinical trial of IV administration of OKN-007 in a pilot cohort of human recurrent malignant glioma patients.
- Trial name
- OKN-007 (NCT01672463)
- Testing
- OKN-007
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Oblato, Inc.
Teratoid Tumor, Atypical, Choroid Plexus Neoplasms
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
This phase I trial studies the side effects and best dose of azurin-derived cell-penetrating peptide p28 (p28) in treating patients with recurrent or progressive central nervous system tumors.
- Conditions
- Teratoid Tumor, Atypical, Choroid Plexus Neoplasms, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT01975116
- Testing
- azurin-derived cell-penetrating peptide p28
- Where
- 11 sites in United States
- Volunteers
- 18 people
- Sponsor
- Pediatric Brain Tumor Consortium
Glioblastoma, Glioma
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
This phase II trial will investigate the efficacy and safety of the addition of Optune (Tumor Treating Fields [TTFields] Therapy) to bevacizumab for patients with bevacizumab-refractory recurrent glioblastoma.
- Conditions
- Glioblastoma, Glioma, Gliosarcoma
- Trial name
- NCT02743078
- Testing
- Bevacizumab, TTFields Therapy
- Where
- 11 sites in United States
- Volunteers
- 3 people
- Sponsor
- RTOG Foundation, Inc.
Constitutional Mismatch Repair Deficiency Syndrome, Lynch Syndrome
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
This phase I trial studies the side effects and best dose of pembrolizumab and to see how well it works in treating younger patients with high-grade gliomas (brain tumors that are generally expected to be fast growing and…
- Conditions
- Constitutional Mismatch Repair Deficiency Syndrome, Lynch Syndrome, Malignant Glioma, Recurrent Brain Neoplasm
- Trial name
- NCT02359565
- Testing
- Biospecimen Collection, Conventional Magnetic Resonance Imaging, Diffusion Tensor Imaging
- Where
- 12 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.